Ra Pharma (RARX) PT Raised to $25 at Credit Suisse; Positive on Upcoming Zilucoplan Data
Tweet Send to a Friend
Credit Suisse analyst Martin Auster raised the price target on Ra Pharma (NASDAQ: RARX) to $25.00 (from $17.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
